These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 29229612)
21. Regulator of G protein signaling 3 protects against cardiac hypertrophy in mice. Liu Y; Huang H; Zhang Y; Zhu XY; Zhang R; Guan LH; Tang Q; Jiang H; Huang C J Cell Biochem; 2014 May; 115(5):977-86. PubMed ID: 24375609 [TBL] [Abstract][Full Text] [Related]
22. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927 [TBL] [Abstract][Full Text] [Related]
23. Stem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overload. Zhou H; Bian ZY; Zong J; Deng W; Yan L; Shen DF; Guo H; Dai J; Yuan Y; Zhang R; Lin YF; Hu X; Li H; Tang QZ Hypertension; 2012 Sep; 60(3):802-9. PubMed ID: 22851736 [TBL] [Abstract][Full Text] [Related]
24. ALK7 protects against pathological cardiac hypertrophy in mice. Huang H; Tang Y; Wu G; Mei Y; Liu W; Liu X; Wan N; Liu Y; Huang C Cardiovasc Res; 2015 Oct; 108(1):50-61. PubMed ID: 26249805 [TBL] [Abstract][Full Text] [Related]
25. JIP3 deficiency attenuates cardiac hypertrophy by suppression of JNK pathway. Ma Q; Liu Y; Chen L Biochem Biophys Res Commun; 2018 Sep; 503(1):1-7. PubMed ID: 29604277 [TBL] [Abstract][Full Text] [Related]
26. Signal regulatory protein-α protects against cardiac hypertrophy via the disruption of toll-like receptor 4 signaling. Jiang DS; Zhang XF; Gao L; Zong J; Zhou H; Liu Y; Zhang Y; Bian ZY; Zhu LH; Fan GC; Zhang XD; Li H Hypertension; 2014 Jan; 63(1):96-104. PubMed ID: 24101669 [TBL] [Abstract][Full Text] [Related]
27. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure. Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233 [TBL] [Abstract][Full Text] [Related]
28. Leukocyte immunoglobulin-like receptor B4 protects against cardiac hypertrophy via SHP-2-dependent inhibition of the NF-κB pathway. Zhou H; Li N; Yuan Y; Jin YG; Wu Q; Yan L; Bian ZY; Deng W; Shen DF; Li H; Tang QZ J Mol Med (Berl); 2020 May; 98(5):691-705. PubMed ID: 32280997 [TBL] [Abstract][Full Text] [Related]
29. Retinol-Binding Protein 4 Induces Cardiomyocyte Hypertrophy by Activating TLR4/MyD88 Pathway. Gao W; Wang H; Zhang L; Cao Y; Bao JZ; Liu ZX; Wang LS; Yang Q; Lu X Endocrinology; 2016 Jun; 157(6):2282-93. PubMed ID: 27100622 [TBL] [Abstract][Full Text] [Related]
30. Hypoxia-Induced Mitogenic Factor Promotes Cardiac Hypertrophy via Calcium-Dependent and Hypoxia-Inducible Factor-1α Mechanisms. Kumar S; Wang G; Liu W; Ding W; Dong M; Zheng N; Ye H; Liu J Hypertension; 2018 Aug; 72(2):331-342. PubMed ID: 29891648 [TBL] [Abstract][Full Text] [Related]
32. Knockout of Eva1a leads to rapid development of heart failure by impairing autophagy. Zhang S; Lin X; Li G; Shen X; Niu D; Lu G; Fu X; Chen Y; Cui M; Bai Y Cell Death Dis; 2017 Feb; 8(2):e2586. PubMed ID: 28151473 [TBL] [Abstract][Full Text] [Related]
33. Novel role for caspase-activated DNase in the regulation of pathological cardiac hypertrophy. Gao L; Huang K; Jiang DS; Liu X; Huang D; Li H; Zhang XD; Huang K Hypertension; 2015 Apr; 65(4):871-81. PubMed ID: 25646292 [TBL] [Abstract][Full Text] [Related]
34. Astragaloside IV protects against the pathological cardiac hypertrophy in mice. Liu ZH; Liu HB; Wang J Biomed Pharmacother; 2018 Jan; 97():1468-1478. PubMed ID: 29793309 [TBL] [Abstract][Full Text] [Related]
35. Cardiac-specific PID1 overexpression enhances pressure overload-induced cardiac hypertrophy in mice. Liu Y; Shen Y; Zhu J; Liu M; Li X; Chen Y; Kong X; Song G; Qian L Cell Physiol Biochem; 2015; 35(5):1975-85. PubMed ID: 25871431 [TBL] [Abstract][Full Text] [Related]
36. SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy. Tang X; Chen XF; Wang NY; Wang XM; Liang ST; Zheng W; Lu YB; Zhao X; Hao DL; Zhang ZQ; Zou MH; Liu DP; Chen HZ Circulation; 2017 Nov; 136(21):2051-2067. PubMed ID: 28947430 [TBL] [Abstract][Full Text] [Related]
37. Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice. Yang J; Mou Y; Wu T; Ye Y; Jiang JC; Zhao CZ; Zhu HH; Du CQ; Zhou L; Hu SJ Cardiovasc Res; 2013 Mar; 97(3):490-9. PubMed ID: 23180723 [TBL] [Abstract][Full Text] [Related]
38. C-C Motif Chemokine Receptor 9 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction. Xu Z; Mei F; Liu H; Sun C; Zheng Z J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146447 [TBL] [Abstract][Full Text] [Related]
39. Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart. Strand ME; Herum KM; Rana ZA; Skrbic B; Askevold ET; Dahl CP; Vistnes M; Hasic A; Kvaløy H; Sjaastad I; Carlson CR; Tønnessen T; Gullestad L; Christensen G; Lunde IG FEBS J; 2013 May; 280(10):2228-47. PubMed ID: 23374111 [TBL] [Abstract][Full Text] [Related]
40. SH2B1 is critical for the regulation of cardiac remodelling in response to pressure overload. Wu G; Liu Y; Huang H; Tang Y; Liu W; Mei Y; Wan N; Liu X; Huang C Cardiovasc Res; 2015 Jul; 107(2):203-15. PubMed ID: 26077624 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]